Andrés Ortíz Restrepo¹, Jeffrey S. Ross², Philippe E. Spiess^3,4,5, Andrea Necchi⁶, Roger Li⁴, Herney Andrés García-Perdomo^1,7

Canadian Journal of Urology, Vol.29, No.6, pp. 11378-11383, 2022

Abstract Introduction: Urothelial carcinoma (UC) is the fourth most prevalent malignancy in adults, accounting for 2.1% of cancer-related deaths. We aimed to describe the most frequent telomerase reverse transcriptase (TERT) gene mutations in this type of cancer and their relationship with the prognosis and treatment of this disease.
Materials and methods: We performed a search strategy in Medline and Embase with the following keywords: telomerase reverse transcriptase (TERT) gene and upper tract UC. We included reviews and observational studies to support the statements throughout the manuscript.
Results: The transcriptional activation of the TERT gene and subsequent telomerase activity is… More >

FANBIAO KONG^1,2,#, KUN WU^3,4,#, LIMING PANG^2,#, YULIANG HUANG^2,#, LEI LI³, JING XU², FEITONG LI², YAN QING², ZHONGYU WANG², XIURONG HUANG³, SHENG XU², XIAOGANG ZHONG², ZHOU ZHU², XIAOTONG WANG^3,*, JIANRONG YANG^5,*

Oncology Research, Vol.30, No.6, pp. 277-288, 2022, DOI:10.32604/or.2022.027301 - 09 February 2023

Abstract Introduction: Siva-1, as a pro-apoptotic protein, has been shown to induce extensive apoptosis in a number of different cell lines. In our previous study, we showed that overexpressed Siva-1 decreased the apoptosis of gastric cancer cells. So, we believe that it can also work as an anti-apoptotic protein. The present study aimed to determine the specific role of Siva-1 in anticancer drug resistance in gastric cancer in vivo and in vitro and preliminarily reveal the mechanism. Materials and Methods: A vincristine-resistant MKN-28/VCR gastric cancer cell line with stably downregulated Siva-1 was established. The effect of Siva-1 downregulation… More >

SUCHITRA NISHAL¹, VIKAS JHAWAT^1,*, SUMEET GUPTA², PARMITA PHAUGAT¹

Oncology Research, Vol.30, No.5, pp. 221-230, 2022, DOI:10.32604/or.2022.027549 - 03 February 2023

Abstract Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research. It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in… More >

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659 - 05 January 2023

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >

Jiajian Shi¹, Yuchen Chen^1,*, Chentai Peng¹, Linwu Kuang², Zitong Zhang¹, Yangkai Li^2,*, Kun Huang¹

Oncologie, Vol.24, No.4, pp. 613-648, 2022, DOI:10.32604/oncologie.2022.027545 - 31 December 2022

Abstract The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been… More >

Linpei Wang^1,#, Xiaoqiu Ma^2,#, Youqi Chen¹, Jiahui Zhang¹, Jiawei Zhang¹, Wei Wang^1,*, Shaojian Chen^3,*

Oncologie, Vol.24, No.4, pp. 897-912, 2022, DOI:10.32604/oncologie.2022.025693 - 31 December 2022

Abstract Background: MicroRNA-145-5p (miR-145-5p) reportedly inhibits hepatocellular carcinoma (HCC) by targeting ARF6, SPATS2, CDCA3, KLF5, and NRAS, indicating that miR-145-5p plays an important role in the occurrence and development of HCC by regulating the expression of various genes. In this study, we aimed to explore novel downstream targets of miR-145-5p and elucidate the potential mechanism of miR-145-5p in HCC. Materials and Methods: A bioinformatics analysis was performed to determine the clinical significance of miR-145-5p and alpha/beta hydrolase domain-containing protein 17C (ABHD17C) in patients with HCC. The ability of Hep3B cells to proliferate, migrate, and invade was examined after… More >

AHMED M. ELSHAZLY^1,2, TUONG VI V. NGUYEN¹, DAVID A. GEWIRTZ^1,*

Oncology Research, Vol.30, No.1, pp. 1-12, 2022, DOI:10.32604/or.2022.026459 - 06 December 2022

Abstract PARP inhibitors have proven to be effective in conjunction with conventional therapeutics in the treatment of various solid as well as hematologic malignancies, particularly when the tumors are deficient in DNA repair pathways. However, as the case with other chemotherapeutic agents, their effectiveness is often compromised by the development of resistance. PARP inhibitors have consistently been reported to promote autophagy, a process that maintains cellular homeostasis and acts as an energy source by the degradation and reutilization of damaged subcellular organelles and proteins. Autophagy can exhibit different functional properties, the most prominent being cytoprotective. In More >

Xin Shu, Qiang Wang^*, Qingming Wu^*

Oncologie, Vol.24, No.3, pp. 427-439, 2022, DOI:10.32604/oncologie.2022.023248 - 19 September 2022

Abstract Liver cancer is ranked as the second leading cause of cancer-related death across the world, and hepatocellular carcinoma (HCC) comprises nearly 90% of all primary liver cancer cases. However, until now, the pathological mechanisms underlying HCC oncogenesis and development remains largely unclear. Eph receptors and their ephrin ligands (Eph/Ephrin system) are involved in various physiological process, such as embryogenesis, neuronal migration, immune response and vascular development. Recently, emerging evidence has showed that the Eph/Ephrin system also plays an essential role in initiation and development of multiple types of cancer, including liver cancer. The Eph/Ephrin system More >

XINLU GAO^1,2,#, XIUXIU WANG^1,2,#, WENWEN ZHANG^1,2,#, HANJING LI^1,2, FAN YANG^2,3, WENYA MA², YU LIU^1,*

BIOCELL, Vol.46, No.12, pp. 2637-2644, 2022, DOI:10.32604/biocell.2022.021033 - 10 August 2022

Abstract Photobiomodulation (PBM) has been shown to delay the pathological process of heart failure, but the exact mechanism of action is not clear. Mitochondria occupy one-third of the volume of mammalian cardiomyocytes (CMs) and are central transport stations for CM energy metabolism. Therefore, in this study, we explored the regulatory effects of 630 nm light-emitting diodes (LED-Red) on the mitochondria of CMs. The results show that LED-Red-based PBM promotes adenosine triphosphate (ATP) synthesis by upregulating the expression of glycolipid metabolizing enzymes. Correspondingly, there was an improvement in the activity of succinate dehydrogenase (SDH), a key enzyme… More >

Bo Yang¹, Zhengxun Guo¹, Jingbo Wang^1,*, Chao Duan², Yaxing Ren³, Yixuan Chen⁴

Energy Engineering, Vol.119, No.5, pp. 1789-1795, 2022, DOI:10.32604/ee.2022.022217 - 21 July 2022

Abstract This article has no abstract. More >